blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1036327

EP1036327 - HLA-E binding to CD94/NKG2+ cells [Right-click to bookmark this link]
Former [2000/38]HLA-E BINDING
[2009/04]
StatusNo opposition filed within time limit
Status updated on  04.06.2010
Database last updated on 05.10.2024
Most recent event   Tooltip07.10.2011Lapse of the patent in a contracting state
New state(s): CY		published on 09.11.2011  [2011/45]
Applicant(s)For all designated states
ISIS INNOVATION LIMITED
Ewert House, Ewert Place Summertown
Oxford OX2 7SG / GB
[2007/44]
Former [2000/38]For all designated states
ISIS INNOVATIONS LIMITED
2 South Parks Road
Oxford, Oxfordshire OX1 3UB / GB
Inventor(s)01 / BRAUD, Veronique, M., Inst. Molecular Medicine
John Radcliffe Hospital
Oxford Oxfordshire OX3 9DS / GB
02 / ALLAN, David, S., J., Inst. Molecular Medicine
John Radcliffe Hospital
Oxford, Oxfordshire OX3 9DS / GB
03 / OGG, Graham, S., Institute of Molecular Medicine
John Radcliffe Hospital
Oxford, Oxfordshire OX3 9DS / GB
04 / O'CALLAGHAN, Christopher, A., Inst. Molecular Med.
John Radcliffe Hospital
Oxford, Oxfordshire OX3 9DS / GB
05 / McMICHAEL, Andrew, J., Inst. Molecular Medicineedi
John Radcliffe Hospital
Oxford, Oxfordshire Ore OX3 9DS / GB
[2000/38]
Representative(s)Campbell, Joanne Marie
Stevens, Hewlett & Perkins
1 St. Augustine's Place
Bristol BS1 4UD / GB
[N/P]
Former [2000/38]Heaton, Joanne Marie
Stevens, Hewlett & Perkins 1 St. Augustine's Place
Bristol BS1 4UD / GB
Application number, filing date98959027.804.12.1998
[2000/38]
WO1998GB03686
Priority number, dateGB1997002576404.12.1997         Original published format: GB 9725764
[2000/38]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO9928748
Date:10.06.1999
Language:EN
[1999/23]
Type: A2 Application without search report 
No.:EP1036327
Date:20.09.2000
Language:EN
The application published by WIPO in one of the EPO official languages on 10.06.1999 takes the place of the publication of the European patent application.
[2000/38]
Type: B1 Patent specification 
No.:EP1036327
Date:29.07.2009
Language:EN
[2009/31]
Search report(s)International search report - published on:EP23.12.1999
ClassificationIPC:G01N33/53
[2000/38]
CPC:
G01N33/56977 (EP,US); C07K16/2896 (US); A61P15/00 (EP);
A61P15/08 (EP); A61P31/00 (EP); A61P31/12 (EP);
A61P31/18 (EP); A61P31/22 (EP); A61P35/00 (EP);
A61P35/02 (EP); A61P37/00 (EP); A61P37/02 (EP);
A61P37/04 (EP); A61P37/06 (EP); C07K16/2851 (US);
C07K2317/76 (US); G01N2333/70539 (EP,US); G01N2333/7056 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2000/38]
TitleGerman:HLA-E Bindung zu CD94/NKG2+ Zellen[2009/04]
English:HLA-E binding to CD94/NKG2+ cells[2009/04]
French:Liaison de HLA-E aux cellules CD94/NKG2+[2009/04]
Former [2000/38]HLA-E BINDUNG
Former [2000/38]HLA-E BINDING
Former [2000/38]LIAISON HLA-E
Entry into regional phase05.06.2000National basic fee paid 
05.06.2000Designation fee(s) paid 
05.06.2000Examination fee paid 
Examination procedure05.07.1999Request for preliminary examination filed
International Preliminary Examining Authority: EP
07.06.2000Examination requested  [2000/38]
08.03.2005Despatch of a communication from the examining division (Time limit: M06)
08.08.2005Reply to a communication from the examining division
07.03.2006Despatch of a communication from the examining division (Time limit: M06)
27.07.2006Reply to a communication from the examining division
26.09.2007Despatch of a communication from the examining division (Time limit: M06)
23.01.2008Reply to a communication from the examining division
09.02.2009Communication of intention to grant the patent
29.05.2009Fee for grant paid
29.05.2009Fee for publishing/printing paid
Divisional application(s)EP09165917.7  / EP2144065
Opposition(s)03.05.2010No opposition filed within time limit [2010/27]
Fees paidRenewal fee
11.12.2000Renewal fee patent year 03
07.12.2001Renewal fee patent year 04
04.12.2002Renewal fee patent year 05
02.01.2004Renewal fee patent year 06
07.12.2004Renewal fee patent year 07
05.12.2005Renewal fee patent year 08
05.12.2006Renewal fee patent year 09
06.12.2007Renewal fee patent year 10
01.10.2008Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT29.07.2009
BE29.07.2009
CY29.07.2009
DK29.07.2009
FI29.07.2009
IT29.07.2009
NL29.07.2009
SE29.07.2009
GR30.10.2009
ES09.11.2009
PT29.11.2009
IE04.12.2009
LU04.12.2009
CH31.12.2009
LI31.12.2009
[2011/45]
Former [2011/25]AT29.07.2009
BE29.07.2009
DK29.07.2009
FI29.07.2009
IT29.07.2009
NL29.07.2009
SE29.07.2009
GR30.10.2009
ES09.11.2009
PT29.11.2009
IE04.12.2009
LU04.12.2009
CH31.12.2009
LI31.12.2009
Former [2010/28]AT29.07.2009
BE29.07.2009
DK29.07.2009
FI29.07.2009
NL29.07.2009
SE29.07.2009
ES09.11.2009
PT29.11.2009
Former [2010/19]AT29.07.2009
FI29.07.2009
NL29.07.2009
SE29.07.2009
ES09.11.2009
PT29.11.2009
Cited inInternational search[X]JPH03112487  ;
 [X]JPH03112486  ;
 [X]JPH03112485  ;
 [PX]  - BORREGO, FRANCISCO ET AL, "Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94 /NKG2 confers protection from natural killer cell-mediated lysis.", JOURNAL OF EXPERIMENTAL MEDICINE, (MARCH 2, 1998) VOL. 187, NO. 5, PP. 813-818., XP002109019 [PX] 1-8,14-17,20-23 * the whole document *

DOI:   http://dx.doi.org/10.1084/jem.187.5.813
 [PX]  - BRAUD, VERONIQUE M. (1) ET AL, "HLA - E binds to natural killer cell receptors CD94 /NKG2A, B and C.", NATURE (LONDON), (FEB. 19, 1998) VOL. 391, NO. 6669, PP. 795-799., XP002109020 [PX] 1-8,14-17,20-23 * the whole document *

DOI:   http://dx.doi.org/10.1038/35869
 [PX]  - O'CALLAGHAN ET AL, "Structural features impose tight peptide binding specificity in the classical MNC molecule HLA-E", MOLECULAR CELL, (199803), vol. 1, no. 4, page 531-541, XP002109609 [PX] 1-8,14-17,20-23 * page 538, column R, paragraph 3 - page 539, column L, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/S1097-2765(00)80053-2
 [PX]  - LEIBSON P. J, "Cytotoxic lymphocyte recognition of HLA-E: Utilizing a nonclasical window to peer into classical MHC", IMMUNITY, (199809), vol. 9, no. 3, pages 289 - 294, XP002109610 [PX] 1-8,14-17,20-23 * page 291, column L, paragraph 3 - page 292, column R, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/S1074-7613(00)80611-1
 [PX]  - POSCH ET AL, "HLA-E is the ligand for the natural killer cell CD94/NKG2 receptors", J.BIOMED.SCI, (199809), vol. 5, no. 5, pages 321 - 331, XP002109611 [PX] 1-8,14-17,20-23 * the whole document *

DOI:   http://dx.doi.org/10.1159/000025346
 [PX]  - LEE ET AL, "HLA-E bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors", EUR.J.IMMUN., (199809), vol. 28, no. 9, pages 2854 - 2863, XP002109612 [PX] 1-8,14-17,20-23 * the whole document *

DOI:   http://dx.doi.org/10.1002/(SICI)1521-4141(199812)28:12<4188::AID-IMMU4188>3.0.CO;2-B
 [PX]  - O'CALLAGHAN ET AL, "Structure & function of the human MNC class 1b molecules HLA-A, -E, -F and HLA-G", IMMUNOL.REV., (1998), vol. 163, pages 129 - 138, XP002109613 [PX] 1-8,14-17,20-23 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1600-065X.1998.tb01192.x
 [X]  - PATENT ABSTRACTS OF JAPAN, (19910802), vol. 015, no. 302, Database accession no. (C - 0855), & JP03112487 A 19910514 (OLYMPUS OPTICAL CO LTD) [X] 9-13,18,19 * abstract *
 [X]  - PATENT ABSTRACTS OF JAPAN, (19910802), vol. 015, no. 302, Database accession no. (C - 0855), & JP03112486 A 19910514 (OLYMPUS OPTICAL CO LTD) [X] 9-13,18,19 * abstract *
 [X]  - PATENT ABSTRACTS OF JAPAN, (19910802), vol. 015, no. 302, Database accession no. (C - 0855), & JP03112485 A 19910514 (OLYMPUS OPTICAL CO LTD) [X] 9-13,18,19 * abstract *
Examination   - SÖDERSTRÖM K. ET AL, "CD94/NKG2 is the predominant inhibitory receptor involved in recognition of HLA-G by decidual and peripheral blood NK cells.", J. IMMUNOL., (19970801), vol. 159, pages 1072 - 1075
    - ULBRECHT M. ET AL, "Impaired intracellular transport and cell surface expression of nonpolymorphic HLA-E: Evidence for inefficient peptide binding.", J. EXP. MED., (199210), vol. 176, pages 1083 - 1090
    - LE BOUTEILLER P. ET AL, "Antigen-presenting function(s) of the non-classical HLA-E, -F and -G class I molecules: the beginning of a story.", RES. IMMUNOL., (1996), vol. 147, no. 5, pages 301 - 313
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.